GSK, Vir's COVID antibody put on ice as BA.2 subvariant takes hold Takeda's gene therapy hunger not yet quelled as Evozyne pact extended for $400M in biobucks Merck, during a transition year, doled out nearly $30M to its pair of CEOs RAND: Broad geographic variation in hospitals' commercial prices spells opportunity for cost reduction policy GlaxoSmithKline recruits PathAI to bring digital pathology AI to cancer, NASH drug development Bluebird bio cuts 30% of its workforce as gene therapy dreams dashed in Europe, delayed in US Through 'serial de-risking,' Sage is getting closer to building an Alzheimer's contender Walmart Health is opening its latest clinics in Florida. Here's how they fit into its 'omnichannel' vision BioNTech CEO's pay fell last year, but he's still a billionaire thanks to holdings in mRNA specialist String of NIH departures continues as Ned Sharpless, head of the National Cancer Institute, steps down Ginkgo Bioworks tightens DNA ties with Twist Bioscience to fuel expansion plans More lawmakers ratchet up pressure on CMS to overturn Aduhelm coverage proposal Phase 3 rare disease failure extends Theravance's losing streak Bioventus picks up partner CartiHeal in acquisition deal worth up to $450M 'We've always had the answers': Put underserved patients in the driver's seat to improve outcomes, leaders say at Health Datapalooza Featured Story | By Eric Sagonowsky Throughout the COVID-19 pandemic, emerging variants have prompted regulators to force antibody products off the market if testing showed that they had stopped working. Now, GlaxoSmithKline and Vir Biotechnology are the latest victims as the FDA has revoked their emergency use authorization for Xevudy. read more |
| |
|---|
|
Top Stories By Annalee Armstrong It’s all about the proteins for Takeda’s latest pact with molecular engineering company Evozyne. Under a deal worth up to $400 million down the line, they'll work together to develop new proteins that can be incorporated into the next generation of gene therapy for rare diseases. read more By Kevin Dunleavy With Merck taking the reins from retiring CEO Ken Frazier and handing them to Robert Davis at the exact midway point of 2021, how would the New Jersey-based drugmaker divvy up their pay for the year? In an unusual bit of symmetry, while Davis saw his pay package increase by $6.9 million last year, Frazier saw his decline by the same amount. read more By Dave Muoio While the average prices hospitals charged to commercial payers from 2012-2019 were "relatively stable" compared to Medicare on the national level, a new study also found substantial upward and downward movement within individual hospital referral regions. read more By Andrea Park After making its first foray into nonalcoholic steatohepatitis (NASH) drug development with a $1 billion RNAi therapy partnership last fall, GlaxoSmithKline is continuing to carve its own path in the race to develop the first FDA-approved NASH treatment. read more By Angus Liu The multiple R&D, regulatory and commercialization setbacks have hit home for bluebird bio. Hoping to keep the business afloat, the gene therapy specialist has brought out the cost-cutting ax. read more By Annalee Armstrong Anytime an Alzheimer’s disease treatment generates data suggesting it can improve cognitive function, a murmur goes through the patient and caregiver communities. Could this be the one? Sage Therapeutics is presenting a study just like that this week at the American Academy of Neurology’s annual meeting, but the company’s chief development officer Jim Doherty, Ph.D., admits there’s still a lot to learn. read more By Paige Minemyer Walmart Health will start to open its next slate of clinics beginning today, with five locations planned for Florida. read more By Angus Liu BioNTech CEO Ugur Sahin is taking a big pay cut in 2021, but his large stake in the German company he co-founded still qualifies him for billionaire status. read more By Max Bayer Ned Sharpless, head of the National Cancer Institute, is stepping down at the end of the month. His decision to leave is the latest in a string of departures of top leadership at the National Institutes of Health. read more By Conor Hale After eating up about one billion base pairs to fuel its synthetic biology and cell programming efforts, Ginkgo Bioworks is going back for seconds, with another large order from the DNA weaver Twist Bioscience. read more By Robert King More and more lawmakers are putting pressure on CMS to overturn its proposal to have Medicare only cover the Alzheimer's disease drug Aduhelm for beneficiaries in qualifying clinical trials. read more By Nick Paul Taylor Theravance Biopharma’s losing streak is going on and on and on. After going 0 for 3 last year, the biotech added another failure to its portfolio late on Monday when it disclosed a phase 3 flop in a blood pressure disorder and pointed to a subgroup analysis as a potential path forward. read more By Andrea Park In a deal nearly two years in the making, Bioventus has opted to acquire fellow orthopedic devicemaker CartiHeal—less than a week after CartiHeal announced its flagship cartilage repair implant Agili-C had been approved by the FDA. read more By Rebecca Torrence FDA Commissioner Robert Califf, M.D., and others urged healthcare to prioritize rural residents and non-White patients in health data reform efforts at the 2022 Health Datapalooza and National Health Policy Conference in Arlington, VA. read more |
